Shingles Vaccine Linked to 24% Lower Dementia Risk in Older Adults

Key Points:

• A new study found that older adults who received the recombinant shingles vaccine Shingrix after admission to skilled nursing facilities were 24% less likely to be diagnosed with dementia within four years compared to unvaccinated peers.
• The research analyzed Medicare data and health records of over 500,000 adults aged 66 and older, using a target trial emulation method to mimic randomized clinical trial conditions.
• Among vaccinated participants, 18.8% developed dementia within four years versus 24.6% of unvaccinated adults, suggesting that about one in 17 dementia cases could potentially be prevented by the vaccine.
• Although the study adjusted for age and health differences, it cannot definitively prove causation, and further clinical trials are needed to confirm whether Shingrix directly reduces dementia risk.
• The findings indicate that the shingles vaccine may offer neuroprotective benefits beyond preventing shingles, highlighting a possible link between physical health interventions and cognitive health maintenance.